Bev improves the immunosuppressive tumor microenvironment caused by Vascular Endothelial Growth Factor (VEGF)-induced inhibition of dendritic cell maturation and tumor angiogenesis by promoting infiltration of the tumor by activated CD8-positive T cells. Here, CD8A is linked to neoplasm.